Avacta Group Plc

AIM:AVCT Stock Report

Market Cap: UK£165.4m

Avacta Group Valuation

Is AVCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AVCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVCT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVCT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVCT?

Key metric: As AVCT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AVCT. This is calculated by dividing AVCT's market cap by their current revenue.
What is AVCT's PS Ratio?
PS Ratio7.3x
SalesUK£22.62m
Market CapUK£165.39m

Price to Sales Ratio vs Peers

How does AVCT's PS Ratio compare to its peers?

The above table shows the PS ratio for AVCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.6x
BVXP Bioventix
14.4xn/aUK£195.7m
AREC Arecor Therapeutics
5.9x35.2%UK£28.9m
TRX Tissue Regenix Group
1.7x15.1%UK£43.5m
OXB Oxford Biomedica
4.4x21.0%UK£432.0m
AVCT Avacta Group
7.3x14.3%UK£165.4m

Price-To-Sales vs Peers: AVCT is expensive based on its Price-To-Sales Ratio (7.3x) compared to the peer average (6.6x).

Price to Sales Ratio vs Industry

How does AVCT's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.40b
OXB Oxford Biomedica
4.4x21.0%US$544.58m
TRX Tissue Regenix Group
1.7x15.1%US$54.78m
VRCI Verici Dx
2.4x78.8%US$10.32m
AVCT 7.3xIndustry Avg. 7.8xNo. of Companies8PS020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AVCT is good value based on its Price-To-Sales Ratio (7.3x) compared to the European Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is AVCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.3x
Fair PS Ratio2.3x

Price-To-Sales vs Fair Ratio: AVCT is expensive based on its Price-To-Sales Ratio (7.3x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AVCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.45
UK£1.09
+141.9%
55.6%UK£1.88UK£0.40n/a3
Nov ’25UK£0.54
UK£1.09
+102.5%
55.6%UK£1.88UK£0.40n/a3
Oct ’25UK£0.45
UK£1.09
+143.0%
55.6%UK£1.88UK£0.40n/a3
Sep ’25UK£0.71
UK£1.09
+52.9%
55.6%UK£1.88UK£0.40n/a3
Aug ’25UK£0.66
UK£1.10
+66.7%
55.2%UK£1.88UK£0.40n/a3
Jul ’25UK£0.53
UK£1.10
+109.5%
55.2%UK£1.88UK£0.40n/a3
Jun ’25UK£0.40
UK£0.82
+103.8%
36.4%UK£1.05UK£0.40n/a3
May ’25UK£0.47
UK£0.92
+97.5%
17.2%UK£1.05UK£0.70n/a3
Apr ’25UK£0.50
UK£0.92
+85.6%
17.2%UK£1.05UK£0.70n/a3
Mar ’25UK£0.55
UK£1.28
+134.2%
34.1%UK£1.75UK£0.70n/a3
Feb ’25UK£1.05
UK£1.43
+36.4%
32.3%UK£1.90UK£0.70n/a4
Jan ’25UK£1.17
UK£1.38
+18.4%
31.6%UK£1.90UK£0.70n/a4
Dec ’24UK£1.35
UK£1.59
+18.0%
36.3%UK£2.28UK£0.70n/a4
Nov ’24UK£1.42
UK£1.89
+33.1%
16.1%UK£2.28UK£1.54UK£0.543
Oct ’24UK£1.23
UK£1.89
+54.3%
16.1%UK£2.28UK£1.54UK£0.453
Sep ’24UK£1.05
UK£2.07
+96.7%
10.4%UK£2.28UK£1.85UK£0.712
Aug ’24UK£0.94
UK£2.07
+119.7%
10.4%UK£2.28UK£1.85UK£0.662
Jul ’24UK£1.08
UK£2.07
+92.1%
10.4%UK£2.28UK£1.85UK£0.532
Jun ’24UK£1.04
UK£2.07
+98.6%
10.4%UK£2.28UK£1.85UK£0.402
Nov ’23UK£1.24
UK£1.87
+50.8%
17.1%UK£2.19UK£1.55UK£1.422

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€820.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€46.50

7D

-3.8%

1Y

-26.2%

hVIVO

UK£172.8m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

7D

-10.9%

1Y

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.35

7D

7.7%

1Y

-14.5%